OTOH hand if they did try to supply the entire market, Sanofi would launch an AG and Sandoz would be stuck with an overcapacity, expired drug etc. Not to mention there's risk that a 3rd party someday may be approved.
I expect Sandoz to aim for about a 60% share, 50% dollar share.
One problem for consumers is some health care plans may bump up the co-pay for the brand when the generic may well not be readily available in their area.
Market Data 
Markets 
AI
